© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Bafilomycin A1 first came to light through the endless search for new antibiotics in soil samples during the 1980s. Researchers uncovered this macrolide compound from a Streptomyces species, and its journey took off not in a typical clinical way, but as a powerful biological probe and a tool for cell biology. Early days involved painstaking fermentation and extraction from natural sources, showing just how much human curiosity and technology drive each other forward. Unlike blockbuster antibiotics, Bafilomycin A1 didn’t wind up in pharmacies but in research labs, shaping understanding of cell organelles and the foundations of cellular health and disease. My experience reviewing historical drug discovery teaches that the true value of a compound often appears through how researchers pick up a molecule and run in unexpected directions, chasing scientific mystery more than clinical markets.
Bafilomycin A1 isn’t a household name, but it has grown into a research staple. As a selective inhibitor of vacuolar-type H+-ATPase (V-ATPase), Bafilomycin A1 blocks acidification in intracellular compartments—lysosomes, endosomes, and more. This blockade impacts everything from pH regulation and protein degradation to autophagy. Among research chemicals, few are as specific or as widely borrowed into such varied disciplines. Anyone working with lysosomal function or autophagy inhibitors has probably handled a vial of Bafilomycin A1.
In the lab, Bafilomycin A1 appears as a yellowish, somewhat waxy solid. Its molecular structure features a large 16-membered lactone ring with a series of conjugated double bonds, methyl branches, and an extended side chain—a setup shaped by biological evolution for potency and selectivity. It offers a molecular weight around 622 daltons and dissolves best in organic solvents like DMSO, ethanol, or methanol. Its sensitivity to air and light forces careful storage—most research stocks sit at -20°C, sealed from moisture, which recalls how hands-on care supports experimental stability. Improper handling can easily spoil a batch, and you only need to lose one tube to learn the value of a dark, cold freezer.
Experts recommend keeping concentrations low, hovering in the nanomolar to low micromolar range for cell-based work. Suppliers typically label Bafilomycin A1 with strict warning icons and detailed storage guidelines emphasizing chemical instability under ambient conditions. Batch-to-batch purity remains a talking point among researchers: faint variations in supplier protocols or aging during shipping can alter the outcomes of tricky experiments. Over years of bench work, I’ve seen entire lab meetings pivot on discussions of purity and batch origin, proving that fine print and well-maintained inventory logs matter as much as the compound itself.
Producing Bafilomycin A1 on a useful scale relies on microbial fermentation rather than synthetic chemistry. The biosynthetic pathway encoded in Streptomyces allows for modest yields after several days’ growth in nutrient-rich media. Downstream processes feature solvent extraction and chromatography to sequence out the active from closely related siblings, and this expertise remains centralized in a few outfits with deep expertise in actinomycete fermentation. There’s real skill in teasing out the pure macrolide—the mixture coming off the first fermenter rarely holds a single peak on an HPLC trace. Over the years, semi-synthetic analogues have also emerged by chemical modification of the parent structure, catering to the need for better stability, improved activity, or finer control of cellular effects.
The structure’s reactive sites—multiple hydroxyls, the lactone, and polyene regions—offer ripe spots for chemical tinkering. Researchers have adjusted Bafilomycin A1 at these positions, aiming to probe structure-activity relationships or tune pharmacokinetics. Modifications sometimes focus on generating less toxic analogues or on introducing labels for imaging studies. The efforts to alter macrolide antibiotics trace a bigger movement in chemical biology: understanding how function couples to form, one atom at a time.
I’ve seen Bafilomycin A1 listed in catalogs under names such as “Baf A1,” “Fungicidin A1,” and “Bafilomycin A” along with chemical registry numbers. Such diversity in nomenclature creates headaches for database searches and experimental reproducibility. Clear synonym mapping, rooted in international chemical registries, helps labs avoid costly mix-ups—a lesson hammered home each time two vials arrive labeled differently but containing the same substance.
Anyone working with Bafilomycin A1 knows not to drop safety precautions. Its high bioactivity and potential to disrupt essential cellular mechanisms mean gloves, lab coats, and careful bench technique are the basic standard. The compound’s environmental persistence also prompts cold-chain storage and special disposal procedures. While Bafilomycin A1 isn’t widely regulated for environmental release, lab safety officers still treat it with respect. Over years of handling chemicals, I’ve found complacency creeps in fastest with familiar molecules—incident logs and hard lessons remind even veteran hands not to downplay hazard just because a molecule sits in the research realm.
Bafilomycin A1’s strongest impact lands in basic and translational research. Cell biologists count on it to probe lysosomal acidification and autophagy—a field that exploded in relevance after the 2016 Nobel Prize in Physiology or Medicine. Cancer researchers test Bafilomycin A1’s ability to block autophagy-driven resistance; neurobiology labs use it to tease apart lysosomal defects tied to neurodegenerative diseases like Parkinson’s or Alzheimer’s. Beyond eukaryotes, it's even found use probing membrane pH changes in some bacteria. This tool drug weaves through modern questions about cell health, survival, and disease—and everywhere it’s used, researchers debate concentrations, exposure times, off-target effects, and the best positive and negative controls.
The pace at which Bafilomycin A1 research has grown illustrates the hunger for reliable molecular disruptors. Since the early 2000s, papers referencing it have multiplied, with studies spanning mechanism-of-action, synthetic modifications, and broader disease models. As scientists map the autophagy-lysosome system in ever-finer detail, Bafilomycin A1 often anchors the controls. I’ve seen entire PhD projects live or die by its quality and availability. Its role as a gold standard V-ATPase inhibitor invites competitors—both small molecules and biological tools—each racing to improve selectivity or safety. Collaboration between chemists, molecular biologists, and biotechs keeps shaking up how Bafilomycin A1 and similar tools evolve, drawing on open-access data and cross-disciplinary knowledge.
Toxicology remains a big shadow on Bafilomycin A1’s otherwise celebrated record. The same potent ability to disrupt V-ATPase function spells trouble for healthy cells in complex tissues or living organisms. Data shows Bafilomycin A1 causes cell death and disrupts mitochondrial function at concentrations barely above those used in routine studies. Animal tests found neurotoxicity, limiting the ambitions of researchers considering therapeutic routes. It reminds the scientific community that “research tool” doesn’t mean “safe as water”—a fact echoed by regulators and institutional safety committees. Having seen how easily one compound moves from bench to preclinical exploration, transparency about toxicity must stay non-negotiable.
Looking ahead, Bafilomycin A1’s future likely stays wedged in research. Next-gen V-ATPase inhibitors with tweaked structures or delivery systems may one day minimize toxicity, opening real clinical utility against drug-resistant infections, cancers, or metabolic disorders. Right now, labs focus on dissecting downstream pathways and combining Bafilomycin A1 with genetic or pharmacological tools, hoping for systems-level insights. Chemical biology will push for engineered derivatives with tags, greater solubility, or improved shelf-life. The demand for robust, transparent safety data will only increase as the chemical toolbox expands, so every research team benefits from deep literature dives and an open mind about alternative tools.
Bafilomycin A1 often pops up in research circles, mostly because of its ability to block a group of enzymes called V-ATPases. These enzymes play a big role in keeping certain structures inside cells—the lysosomes and vacuoles—at the right level of acidity. If you mess with these enzyme pumps, you end up changing how cells digest and sort their waste. This is why scientists like using Bafilomycin A1 to explore basic cell biology questions, from how cells break down their garbage to understanding diseases linked to faulty recycling, like Alzheimer's or Parkinson's disease.
Blocking V-ATPases with Bafilomycin A1 doesn’t just leave cells with a mess. It gives researchers a peek at how quickly cells can adapt when their inner recycling systems fail. My own time in the lab showed me that even a short-term block can stress some cells, making certain cancer or nerve cells stand out. This turns Bafilomycin A1 into a kind of flashlight, exposing the vulnerable spots in disease models and letting scientists pick apart where therapies might go wrong.
The relationship with mTOR, another key pathway involved in growth and survival, brings extra attention to this molecule. By getting in the way of acidification, Bafilomycin A1 helps clarify how cells sense and respond to nutrients. Scientists use this knowledge to brainstorm new cancer treatment angles, since tumors often hijack these same pathways.
Using Bafilomycin A1 isn’t risk-free. This molecule doesn’t distinguish between cell types—so it can shut down healthy systems along with the unhealthy ones. In animal studies, even small amounts spark issues for heart, nerve, and liver function. These effects limit its use to the lab instead of the hospital, despite big curiosity about what stopping V-ATPases could do in real patients. Lab researchers need to stay cautious and double-check results, since changes in pH can twist readings from certain experiments.
Drug development teams see promise in the Bafilomycin story but know better than to copy it directly. Structure-inspired drug design is making progress, with molecules tuned to hit only certain V-ATPase subtypes. Targeting subunits unique to cancer or infection might dodge the worst side-effects. Funding agencies and biotech start-ups are throwing support behind more precise drug candidates, especially as we learn more about V-ATPases’ roles in cell metabolism, infections, and rare genetic conditions.
Every year, thousands of experiments involve Bafilomycin A1—from examining how bacteria resist antibiotics to breaking down tough-to-treat cancers in cell lines. The molecule remains one of the sharpest arrows in the cell biology toolbox for asking detailed questions about acid regulation and waste removal. As labs around the world keep pushing for new treatments in neurodegeneration or cancer, lessons from Bafilomycin A1 are guiding the next chapter of more targeted, safer drugs.
Bafilomycin A1 may sound like an uncomfortable term tossed around in a science classroom, but it’s a name that comes up more often for researchers dealing with cells and disease. What matters most? This compound turns a wrench in the gears of cellular recycling, shaping many kinds of experiments and making scientists rethink how our bodies manage waste and infection.
Think of a cell as a busy city. There’s traffic, maintenance, trash pickup. The lysosome works as the garbage disposal, digesting unwanted debris. For this, lysosomes rely on a high-acidity environment. Bafilomycin A1 blocks the vacuolar-type H+-ATPase, or V-ATPase—a protein pump needed for this acidification. Without that acidic bath, the lysosome cannot do its job. Debris piles up. Essential proteins no longer break down effectively. Cells get stressed, structures malfunction, and warning lights start flashing across the system.
Researchers use Bafilomycin A1 to study more than just clean-up time. Some look at how it halts autophagy, the process cells use to clean out and recycle parts when things get tough or when nutrients run low. By disrupting the V-ATPase, the compound keeps those cell-cleaning vesicles from merging properly with lysosomes. Scientists can freeze floods of half-eaten garbage inside cells, then photograph the scene. These studies help explain why faulty clean-up links to aging, neurodegenerative diseases, and certain cancers. If you ever meet a neurologist talking about protein clumps in Alzheimer’s, interruptions in autophagy are often to blame. Bafilomycin A1 creates a sort of time machine to see what happens inside diseased cells, offering clues that might not show up otherwise.
No chemical comes without concern. Bafilomycin A1 does more than block lysosomes. It drops the pH in endosomes, changes calcium movement, and even interferes with infection cycles of some viruses and bacteria. Block too many V-ATPase pumps, and healthy cells begin to suffer, especially in organs with high recycling needs such as the liver or kidneys. This makes it a dangerous tool for anything beyond the lab, since you quickly move from learning mode to real harm.
Questions now swirl around how to use this knowledge safely. Targeting specific V-ATPase subunits offers a precision approach, but finding drugs that pick only the right pump in the right place is still tough. Synthetic chemists and cell biologists share a common hope: smarter compounds with narrower focus, leaving essential systems alone but blocking disease-related recycling. There’s movement in drug development for cancer research, especially for tumors that use autophagy to survive chemo or poor blood flow.
Bafilomycin A1 shaped an era of discovery. Still, it reminds every investigator that hijacking basic cell machinery holds promise but also risk. Knowledge builds up one carefully chosen tool at a time. For now, the story of Bafilomycin A1 still drives both curiosity and caution in modern research labs.
Bafilomycin A1 isn’t something you find on pharmacy shelves. Scientists rely on its precision as an inhibitor of vacuolar ATPases, unlocking clues in cell biology, microbiology, and even cancer research. Unlike a bottle of aspirin forgotten in the medicine cabinet, Bafilomycin A1 stays useful only if handled with respect for its chemistry. Its structure, a macrocyclic lactone antibiotic produced by Streptomyces species, carries sensitive moieties that react to moisture, heat, and light. Just one mistake can turn an expensive chemical into a useless powder.
I’ve stored dozens of rare compounds in the lab. Bafilomycin A1 holds up best at low temperatures. Manufacturers and researchers agree on -20°C as a gold standard. At this range, bacterial inhibitors maintain their punch and chemical makeup. Keeping it colder, like deep freezer or liquid nitrogen storage, runs the risk of humidity sneaking in every time the vial leaves the ice. I’ve seen freeze-and-thaw cycles destroy delicate solutes, forming clumps you can’t redissolve and draining valuable budgets. So, steady placement in a -20°C freezer preserves activity without drama.
Direct sun isn’t a friend to most sensitive molecules, least of all to light-reactive ones like Bafilomycin A1. Researchers avoid transparent plastic, using amber-colored vials instead. That piece of brown glass isn’t old-fashioned; it puts up a shield against UV damage. Inside the lab, nobody leaves a vial uncapped or outside the fridge for long, since humidity spells disaster. Moisture finds its way into almost any container. My colleagues and I tap silica gel packets or store vials in a dry box for backup protection. Small steps make a world of difference: if the powder absorbs even a bit of water, its potency crashes quick.
Opening a stock only in a dry environment, weighing out just the amount needed with clean tools, and sealing the remainder tight—these steps have saved plenty of experiments from failure. I recommend using screw-capped, airtight vials, ideally with rubber liners. Once you have a working solution, whether in DMSO or ethanol, label both the date and concentration. That recordkeeping keeps everyone on track and limits those awkward moments of guessing shelf life. Freshly prepared solutions go back in the fridge, wrapped in foil or kept in a dark drawer.
Manufacturers publish shelf life for a reason. Reagents rarely announce their decline until results start sliding. If the product’s been open for several months, it’s usually wise to test a small batch before using it on irreplaceable samples. Always check for clumpy texture, color change, or strange smells. Even with strict storage, accidents happen—spills, broken vials, or power outages. Bafilomycin A1 does carry health risks, so gloves, goggles, and good ventilation matter as much as storage conditions.
Bafilomycin A1 fetches a high price, and labs cannot afford waste. By keeping a log of use and conditions, mistakes drop, and supply stretches further. Investing a bit more in quality containers and backup storage delivers better results for researchers and makes sure each milligram counts. It’s all part of the scientific grind—protecting both the work and the people doing it.
Bafilomycin A1 has earned a reputation as an essential tool for researchers digging into lysosomal acidification and autophagy pathways. It blocks the vacuolar-type H+-ATPase, stopping acidification in its tracks. Figuring out the amount to use in experiments isn’t just about reading numbers from someone else’s paper. In my experience, the most useful advice comes less from hard rules and more from what actually works on-hand, cell line by cell line.
Digging through published work and lab protocols, a concentration range pops up again and again: people reach for 10 nanomoles per liter (nM) up to 100 nM in cell systems. Lower than 10 nM, effects may go unnoticed; higher than 100 nM, and toxicity overwhelms most cultured cells. While some investigators try out higher levels, even up to 200 nM, results usually don’t improve, and cells take a hit.
For instance, work from the autophagy field showcases HeLa cells responding solidly between 10–50 nM Bafilomycin A1, with clear inhibition of lysosomal degradation and minimal signs of cell stress. In neurons, even 10 nM climbs high enough to impact survival over more than a few hours. In cancer lines, 50–100 nM hits the sweet spot, with strong activity but less nonspecific toxicity.
In my own experiments, I started at 50 nM—midway on the typical scale. Within three hours, lysosomes swelled, LC3-II increased, and cell health hung in there. Pushing to 100 nM, I watched many cells round up and detach. It matters to set up pilot time-course trials and stain for cell death before settling on any recipe.
A word to labs, especially those with new hands on deck: be mindful of Bafilomycin’s sensitivity to storage and handling. The molecule breaks down fast in solution. Stock up at 1 millimolar in DMSO, don’t keep working dilutions lying around on the bench, and limit freeze-thaw cycles. DMSO concentration can creep up and mess with control wells. Most experienced groups use 0.1% DMSO or less in all wells, controls and treated alike.
Cell density changes things, too. Confluent dishes behave differently than sparse ones. A clean experiment means matching confluency and confirming activity (for example, acridine orange staining or LysoTracker red uptake) at every batch.
Instead of copying protocols flat, a smarter way forward is combining dose-response curves with clear functional readouts for the cell type of interest. Fluorescent live/dead assays can take the guesswork out. Some labs have moved to shorter incubations—say, 2–4 hours—to reduce toxicity, tracking target pathway engagement in real time.
Safety can’t be brushed aside. Always glove up, work in the hood, and record every stock preparation. Nobody in the research world benefits from second-guessing an experiment because the dosing details were fuzzy.
Labs see the best success by treating 10–100 nM as a core window but always testing this range for every new cell type. Trusting published averages or product datasheets isn’t enough. Well-planned early tests, careful monitoring, and smart controls guarantee results you want to stand behind.
Bafilomycin A1 shows up in labs all over the world. It blocks the activity of vacuolar H⁺-ATPase, a type of protein pump necessary for cells to manage their internal acidity. Scientists rely on this compound to study how cells process waste and recycle old parts, which ties into areas like cancer, neurodegenerative disease, and even basic metabolism. The problem starts when conversations turn toward toxicity.
In the Petri dish, Bafilomycin A1 doesn’t treat every cell gently. Common sense and decades of research agree—messing with essential proteins rarely leaves cells untouched. Many teams found that Bafilomycin A1 stops autophagy, a clean-up process, causing debris to pile up inside the cell. Not long after, you notice cells shrinking, swelling, or even bursting. In human epithelial cells and fibroblasts, higher doses above 10-50 nanomolar trigger cell death over time. Cancer cell lines sometimes show resistance, but that’s luck of the draw, not immunity to harm.
Animal studies mostly back this up. In mouse models, even low doses used for just a few hours cause tissue damage or disrupt the balance in organs such as the kidney and liver. Drosophila (fruit fly) experiments report halted growth and developmental failures. Clearly, both dosage and time matter—prolonged exposure ramps up the risks.
While researchers keep animal and human doses extremely low, there’s always a real possibility that leftover Bafilomycin A1 sticks around longer than intended. It’s not something dreamt up in a safety manual; many cleaning crews have had to learn how trace amounts can linger on surfaces. Accidental spills could damage expensive cell lines or even pose risk to other projects, especially in shared facilities.
So, why use Bafilomycin A1 at all? It’s uniquely effective. No other compound cleanly blocks the same pathway. Still, science has to weigh the benefits against the risks. Some safer analogs are in development, but they rarely match the potency researchers expect from Bafilomycin A1. Teams have come up with a few practical ideas:
Transparency matters. If a study features Bafilomycin A1, researchers should state exactly how much they used, how long they exposed the cells or animals, and what side effects they tracked. More journals are pushing for full method sections and published raw datasets, which lets others check those toxicity risks for themselves. Training young scientists on lab safety and chemical hygiene adds another layer of protection, which nobody should treat as optional. The importance of keeping Bafilomycin A1 contained and used only where strictly necessary spans well beyond paperwork—people’s health and research outcomes both ride on those details.
| Names | |
| Preferred IUPAC name | (1R,3S,7S,9S,11E,13E,15R,16R,17R,18S,19E,21S,23R,25S,26R)-21,26-dihydroxy-1,3,9,15,17,23-hexamethyl-25-[(2R)-tetrahydro-2H-pyran-2-yl]oxy]oxacyclohexacosa-11,13,19-triene-2,6,8,14,20-pentaone |
| Other names |
Baf A1 Bafilomycin Bafilomycin A |
| Pronunciation | /ˌbæfɪləˈmaɪsɪn eɪ wʌn/ |
| Identifiers | |
| CAS Number | 88899-55-2 |
| Beilstein Reference | 3593264 |
| ChEBI | CHEBI:9085 |
| ChEMBL | CHEMBL477052 |
| ChemSpider | 181136 |
| DrugBank | DB11851 |
| ECHA InfoCard | 04d386cf-92d7-4cde-a0d5-c6b055e2f44d |
| EC Number | 3.6.3.10 |
| Gmelin Reference | 84887 |
| KEGG | C02013 |
| MeSH | D017953 |
| PubChem CID | 448983 |
| RTECS number | RP2060000 |
| UNII | Q96P8Q8486 |
| UN number | Not assigned |
| Properties | |
| Chemical formula | C35H58O9 |
| Molar mass | 622.736 g/mol |
| Appearance | Yellow solid |
| Odor | Odorless |
| Density | 1.11 g/cm³ |
| Solubility in water | Soluble in DMSO, ethanol; poorly soluble in water |
| log P | 2.76 |
| Vapor pressure | 0 mmHg (25 °C) |
| Acidity (pKa) | 5.6 |
| Basicity (pKb) | 1.48 |
| Magnetic susceptibility (χ) | -6.2E-6 cm^3/mol |
| Refractive index (nD) | 1.601 |
| Viscosity | Viscous oil |
| Dipole moment | 6.02 D |
| Hazards | |
| Main hazards | May cause respiratory irritation. May cause damage to organs through prolonged or repeated exposure. Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. |
| GHS labelling | GHS05, GHS06 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | H302+H332-H315-H319-H335 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 2, Instability: 0, Special: |
| Lethal dose or concentration | LD₅₀ (mouse, intravenous): 1.4 mg/kg |
| PEL (Permissible) | Not established |
| REL (Recommended) | 10 nM |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Bafilomycin B1 Bafilomycin C1 Bafilomycin D Bafilomycin A2 |
